HomeCompareCLHLF vs JNJ

CLHLF vs JNJ: Dividend Comparison 2026

CLHLF yields 5.09% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLHLF wins by $9.22M in total portfolio value
10 years
CLHLF
CLHLF
● Live price
5.09%
Share price
$61.16
Annual div
$3.12
5Y div CAGR
65.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.25M
Annual income
$7,413,102.32
Full CLHLF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CLHLF vs JNJ

📍 CLHLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLHLFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLHLF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLHLF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLHLF
Annual income on $10K today (after 15% tax)
$433.04/yr
After 10yr DRIP, annual income (after tax)
$6,301,136.97/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CLHLF beats the other by $6,297,150.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLHLF + JNJ for your $10,000?

CLHLF: 50%JNJ: 50%
100% JNJ50/50100% CLHLF
Portfolio after 10yr
$4.64M
Annual income
$3,708,895.86/yr
Blended yield
79.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CLHLF
No analyst data
Altman Z
8.0
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLHLF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLHLFJNJ
Forward yield5.09%2.13%
Annual dividend / share$3.12$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR65.7%28%
Portfolio after 10y$9.25M$30.3K
Annual income after 10y$7,413,102.32$4,689.40
Total dividends collected$9.06M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CLHLF vs JNJ ($10,000, DRIP)

YearCLHLF PortfolioCLHLF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,544$844.17$10,592$272.30+$952.00CLHLF
2$13,861$1,509.15$11,289$357.73+$2.6KCLHLF
3$17,638$2,806.19$12,123$472.89+$5.5KCLHLF
4$24,402$5,529.61$13,141$629.86+$11.3KCLHLF
5$37,958$11,847.18$14,408$846.81+$23.6KCLHLF
6$69,152$28,537.96$16,021$1,151.60+$53.1KCLHLF
7$154,507$80,514.06$18,122$1,588.22+$136.4KCLHLF
8$443,904$278,580.98$20,930$2,228.20+$423.0KCLHLF
9$1,714,430$1,239,453.37$24,792$3,191.91+$1.69MCLHLF
10$9,247,543$7,413,102.32$30,274$4,689.40+$9.22MCLHLF

CLHLF vs JNJ: Complete Analysis 2026

CLHLFStock

COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania. It offers restoration products, including conventional composites, bulk-fill composites, CAD/CAM solutions, core build-ups, bondings, etching gels, temporary materials, luting, curing lights, and characterizations; and endodontics products, such as posts, rotary and hand files, irrigation solutions, obturation and sealing materials, Gutta-percha and paper points, endo engines, apex locators, and endo accessories. The company also provides prosthetics comprising bite registration, retractions, A-silicones, C-silicones, and accessories; and treatment auxiliaries consisting of dental rolls and dispensers, cotton pellets and dispensers, aspirator tips, dental dams and dam kits, dental dam clamps and accessories, dental scalers, electrosurgery, and occlusion verification products. In addition, it offers infection control products, which include ultrasonic cleaning units, patient bibs, headrest covers, and sterile covers; rotary instruments, such as diamond and carbide burs, polishers, kits, and accessories; and laboratory products comprising gingiva masks, lab putty products, model making products, waxes, occlusion control products, accessories, HP burs, and silicone polishers. The company was formerly known as Medisize Holding AG and changed its name to COLTENE Holding AG in April 2008. COLTENE Holding AG was incorporated in 2005 and is headquartered in Altstätten, Switzerland.

Full CLHLF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CLHLF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLHLF vs SCHDCLHLF vs JEPICLHLF vs OCLHLF vs KOCLHLF vs MAINCLHLF vs ABBVCLHLF vs MRKCLHLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.